The Role of CXCL13 in Antibody Responses to HIV-1 Infection and Vaccination

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Mar 18

PMID 33732259

Citations 12

Authors

Yonas Bekele Feyissa

Francesca Chiodi

Yongjun Sui

Jay A Berzofsky

Affiliations

Soon will be listed here.

Abstract

CXCL13 signals through the G protein-coupled chemokine receptor CXCR5 to drive development of secondary lymphoid tissue as well as B cell and Tfh cell trafficking to germinal centers (GC), which leads to the differentiation of B cells to plasma cells and memory B cells. CXCL13 has been proposed as a general plasma biomarker for GC activities. In HIV-1 infected individuals, plasma CXCL13 levels have been associated with the rate of disease progression to AIDS. Moreover, CXCL13 production has been reported to be increased in HIV-1-infected lymph nodes, which may drive increased downregulation of CXCR5. In this review, we address the role of CXCL13 in HIV-1 infected individuals with regard to GC formation, generation of broadly neutralizing antibodies after infection and vaccination, and AIDS-related B cell lymphoma.

Citing Articles

CXCL13 promotes broad immune responses induced by circular RNA vaccines.

Wan J, Wang C, Wang Z, Wang L, Wang H, Zhou M Proc Natl Acad Sci U S A. 2024; 121(44):e2406434121.

PMID: 39436660 PMC: 11536096. DOI: 10.1073/pnas.2406434121.

Fentanyl dysregulates neuroinflammation and disrupts blood-brain barrier integrity in HIV-1 Tat transgenic mice.

Rademeyer K, Nass S, Jones A, Ohene-Nyako M, Hauser K, McRae M J Neurovirol. 2024; 30(1):1-21.

PMID: 38280928 PMC: 11232468. DOI: 10.1007/s13365-023-01186-4.

Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations.

Rosati M, Terpos E, Homan P, Bergamaschi C, Karaliota S, Ntanasis-Stathopoulos I Front Immunol. 2023; 14:1292568.

PMID: 38090597 PMC: 10711274. DOI: 10.3389/fimmu.2023.1292568.

An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants.

Tai W, Feng S, Chai B, Lu S, Zhao G, Chen D Nat Commun. 2023; 14(1):2962.

PMID: 37221158 PMC: 10204679. DOI: 10.1038/s41467-023-38751-8.

Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV.

Trunfio M, Mighetto L, Napoli L, Atzori C, Nigra M, Guastamacchia G J Neuroimmune Pharmacol. 2023; 18(1-2):169-182.

PMID: 37166552 DOI: 10.1007/s11481-023-10066-x.

References

Cohen K, Altfeld M, Alter G, Stamatatos L . Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J Virol. 2014; 88(22):13310-21. PMC: 4249103. DOI: 10.1128/JVI.02186-14. View

Mascola J, DSouza P, Gilbert P, Hahn B, Haigwood N, Morris L . Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol. 2005; 79(16):10103-7. PMC: 1182642. DOI: 10.1128/JVI.79.16.10103-10107.2005. View

Havenar-Daughton C, Lindqvist M, Heit A, Wu J, Reiss S, Kendric K . CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A. 2016; 113(10):2702-7. PMC: 4790995. DOI: 10.1073/pnas.1520112113. View

Gauvin J, Chagnon-Choquet J, Poudrier J, Roger M . Fluctuations in Blood Marginal Zone B-Cell Frequencies May Reflect Migratory Patterns Associated with HIV-1 Disease Progression Status. PLoS One. 2016; 11(5):e0155868. PMC: 4874627. DOI: 10.1371/journal.pone.0155868. View

Stephenson K, Barouch D . Broadly Neutralizing Antibodies for HIV Eradication. Curr HIV/AIDS Rep. 2016; 13(1):31-7. PMC: 4779134. DOI: 10.1007/s11904-016-0299-7. View

Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky P . Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol. 2000; 166(1):650-5. DOI: 10.4049/jimmunol.166.1.650. View

Hussain S, Zhu W, Chang S, Breen E, Vendrame E, Magpantay L . Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev. 2012; 22(2):295-307. PMC: 3703445. DOI: 10.1158/1055-9965.EPI-12-1122. View

Mehraj V, Ramendra R, Isnard S, Dupuy F, Lebouche B, Costiniuk C . CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection. Front Immunol. 2019; 10:289. PMC: 6393370. DOI: 10.3389/fimmu.2019.00289. View

Wada N, Bream J, Martinez-Maza O, Macatangay B, Galvin S, Margolick J . Inflammatory Biomarkers and Mortality Risk Among HIV-Suppressed Men: A Multisite Prospective Cohort Study. Clin Infect Dis. 2016; 63(7):984-990. PMC: 5019283. DOI: 10.1093/cid/ciw409. View

10.

Carlsen H, Baekkevold E, Morton H, Haraldsen G, Brandtzaeg P . Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004; 104(10):3021-7. DOI: 10.1182/blood-2004-02-0701. View

11.

Halper-Stromberg A, Nussenzweig M . Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. J Clin Invest. 2016; 126(2):415-23. PMC: 4731188. DOI: 10.1172/JCI80561. View

12.

He X, Holmes T, Zhang C, Mahmood K, Kemble G, Lewis D . Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol. 2006; 80(23):11756-66. PMC: 1642596. DOI: 10.1128/JVI.01460-06. View

13.

Mabuka J, Dugast A, Muema D, Reddy T, Ramlakhan Y, Euler Z . Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies. Front Immunol. 2017; 8:1104. PMC: 5596076. DOI: 10.3389/fimmu.2017.01104. View

14.

Lim H, Hillsamer P, Kim C . Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest. 2004; 114(11):1640-9. PMC: 529283. DOI: 10.1172/JCI22325. View

15.

Kim H, Verbinnen B, Tang X, Lu L, Cantor H . Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature. 2010; 467(7313):328-32. PMC: 3395240. DOI: 10.1038/nature09370. View

16.

Allen C, Ansel K, Low C, Lesley R, Tamamura H, Fujii N . Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004; 5(9):943-52. DOI: 10.1038/ni1100. View

17.

Laestadius A, Ingelman-Sundberg H, Hed Myrberg I, Verme A, Sundberg E, Schweiger B . Altered proportions of circulating CXCR5+ helper T cells do not dampen influenza vaccine responses in children with rheumatic disease. Vaccine. 2019; 37(28):3685-3693. DOI: 10.1016/j.vaccine.2019.05.037. View

18.

Epeldegui M, Lee J, Martinez A, Widney D, Magpantay L, Regidor D . Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). Clin Cancer Res. 2015; 22(2):328-36. PMC: 4715998. DOI: 10.1158/1078-0432.CCR-14-0466. View

19.

Paris R, Milagres L, Moysi E, Okulicz J, Agan B, Ganesan A . Lower Baseline Germinal Center Activity and Preserved Th1 Immunity Are Associated With Hepatitis B Vaccine Response in Treated HIV Infection. Pathog Immun. 2017; 2(1):66-88. PMC: 5450971. DOI: 10.20411/pai.v2i1.175. View

20.

Saeki H, Wu M, Olasz E, Hwang S . A migratory population of skin-derived dendritic cells expresses CXCR5, responds to B lymphocyte chemoattractant in vitro, and co-localizes to B cell zones in lymph nodes in vivo. Eur J Immunol. 2000; 30(10):2808-14. DOI: 10.1002/1521-4141(200010)30:10<2808::AID-IMMU2808>3.0.CO;2-K. View